Forty Seven (FTSV) Prices 4.86M Share Common Offering ar $35/Sh

After-Hours Movers 12/11: (AMRS) (FORM) (TLRD) Higher; (AKTS) (ASMB) (LULU) Lower (more...)

Today's After-Hours Movers

Amyris, Inc. (NYSE: AMRS) 11% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $8.00.

FormFactor, Inc. (Nasdaq: FORM) 10.7% HIGHER; raises Q4 guidance

Akoustis Technologies, Inc. (NASDAQ: AKTS) 6.5% LOWER; announced today that it intends to offer and sell shares of its common stock in an underwritten public... More

Forty Seven (FTSV) to Offer $140M in Common Stock

Forty Seven, Inc. (Nasdaq: FTSV) has commenced an underwritten public offering of $140,000,000 of shares of its common stock. All of the shares of common stock are being offered by Forty Seven. In connection with this offering, Forty Seven expects to grant the underwriters a... More

Forty Seven Inc. (FTSV) PT Raised to $48 at Guggenheim

Guggenheim analyst Michael Schmidt raised the price target on Forty Seven Inc. (NASDAQ: FTSV) to $48.00 (from $20.00) while maintaining a Buy rating.... More

Forty Seven Inc. (FTSV) PT Raised to $35 at Oppenheimer

Oppenheimer analyst Mark Breidenbach raised the price target on Forty Seven Inc. (NASDAQ: FTSV) to $35.00 (from $20.00) while maintaining an Outperform rating.

The analyst commented, "Monday, Forty Seven presented impressive clinical data from its ongoing study evaluating magrolimab in combination with azacitidine (azaC) in front-line... More

Avadel Pharma (AVDL) Announces Dr. Mark McCamish to Board

Avadel Pharmaceuticals plc (NASDAQ: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating narcolepsy, announced today the appointment of Mark McCamish, MD, Ph.D. to its board of directors, effective immediately.

We are pleased to have Dr. McCamish join our board of directors. He brings Avadel tremendous experience as a senior executive overseeing research and development at several leading global companies, including Abbott, Amgen, and Sandoz, stated Mr. Geoffrey Glass, Chairman of the... More

Forty Seven Inc. (FTSV) PT Raised to $36 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Forty Seven Inc. (NASDAQ: FTSV) to $36.00 (from $21.00) while maintaining a Buy rating.... More

Forty Seven Inc. (FTSV) PT Raised to $45 at Morgan Stanley

Morgan Stanley analyst Matthew Harrison raised the price target on Forty Seven Inc. (NASDAQ: FTSV) to $45.00 (from $17.00) while maintaining a Overweight rating.... More

Forty Seven Inc. (FTSV) PT Raised to $38 at Credit Suisse

Credit Suisse analyst Martin Auster raised the price target on Forty Seven Inc. (NASDAQ: FTSV) to $38.00 (from $18.00) while maintaining a Outperform rating.... More

Forty Seven Inc. (FTSV) PT Raised to $37 at Mizuho Securities Not Including Potential Takeout Premium

Mizuho Securities analyst Mara Goldstein raised the price target on Forty Seven Inc. (NASDAQ: FTSV) to $37.00 (from $18.00) following presentation of competitive magrolimab data in 1L MDS.

The analyst reiterated her Buy rating stating "While the shares rallied significantly already, we see the data... More